|
Preclinical
Neuropsychopharmacology Research Team
|
||||
| Left to right: Hugh Criswell, Sophia Papadeas, Thomas McCown, A. Fernandes, Jennifer Price, Edna Titus, Darin Knapp, Zhen Ming, George Breese (P.I.), Nathaniel Pleasant, David Overstreet |
Our Focus
The primary focus of our laboratory is to understand adaptive changes in brain that accompany prolonged drug treatment and lesions to specific neural systems in brain. There are three areas of research which allow the laboratory to maintain the aim of the laboratory. One is an investigation of the adaptive mechanisms that accompany neonatal destruction of dopaminergic neurons. This particular treatment is important because it models the dopamine deficiency observed in Lesch-Nyhan disease.
A variety of techniques are used to evaluate this model including behavioral, pharmacological, electrophysiological, biochemical and anatomical approaches. The second major area of interest is the study of the acute and chronic actions of ethanol on brain function. This work assesses the sedative, anticonflict and seizure producing properties of ethanol.
Multidisciplinary approaches are used to evaluate these actions of ethanol on GABA and NMDA neural mechanisms including anatomical, molecular biological,behavioral and electrophysiological methods. Finally, the laboratory is working to define the site within brain where antidepressant drugs act to effect corticoid release and anxiety present in depression. This latter work utilizes chemical, anatomical and behavioral approaches to define the adaptive changes that accompany chronic antidepressant treatment.
![]() |
| Darin Knapp and Dana Rotella in the lab. |
Neurobiology of Anti-Depressant Drugs
Molecular Basis for Ethanol-GABA Interactions
Molecular Basis of Ethanol Action on NMDA Receptors
CNS Transmitters Involved in Withdrawal-Induced Anxiety
Gene Therapy and Seizures
More Information About the Research Team
Article 1 on this lab's research from the Center Line newsletter
Article 2 on this lab's research from the Center Line newsletter
|
Updated
11/25/2002
|
||